MAPT and tauopathy: Although P-tau217 is thought to primarily reflect amyloid plaque burden (33), these findings suggest that P-tau217 levels may reflect the degree to which amyloid is triggering downstream change, including tauopathy (i.e., “the amyloid is bothering the tau”).